Future worldwide head-to-head RCTs including these regimens (TPO-RAs vs placebo, or direct comparison including eltrombopag, romiplostim, avatrombopag, lusutrombopag, and rhTPO) are essential, to validate our results and to determine the most suitable therapeutic strategies for persistent or chronic ITP in adults. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.